Skip to content

FDA Category 2 · restricted from compounding

This compound is on the FDA’s interim Section 503A Category 2 bulks list and cannot be legally compounded by US pharmacies. An HHS announcement in February 2026 signaled intent to restore several peptides to Category 1, but no Federal Register action has been published. Check the FDA PCAC schedule for updates.

Read the full regulatory context
ExperimentalSleepSubQDailyPartial data

DSIP

Delta Sleep-Inducing Peptide

Nonapeptide associated with delta-wave sleep; used anecdotally for sleep onset and recovery.

§ 01   Overview

Overview

Nonapeptide associated with delta-wave sleep; used anecdotally for sleep onset and recovery.

Limited and inconsistent clinical data. Mostly anecdotal user reports.

§ 02   Mechanism

Mechanism of action

DSIP's exact mechanism is not fully characterized but appears to modulate corticotropin release, opioid signaling, and slow-wave sleep in some studies. Endogenous distribution across CNS and peripheral tissues.

  • 01Potential improvement in deep sleep phases
  • 02Reduced stress response anecdotally

§ 03   Dosing

Dosing protocol

Standard Protocol

Vial
5 mg
BAC Water
2 ml BAC water
Dose Range
100 – 500 mcg pre-bed
Starting Dose
100 mcg
Route
SubQ
Timing
Before bed
Frequency
Daily
Cycle
2–4 weeks, assess

§ 04   Evidence

Evidence & research

Experimental

Limited and inconsistent clinical data. Mostly anecdotal user reports.

FDA Status

Not FDA-approved.

§ 06   News

In the news

5 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Restricted from compounding

Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales.

Research-use-only · 1

Research-use-only

Core Peptides

Broad catalog, widest payment range. Mid-credibility: Knoji 2.5/5 and one scam-impersonation report.

Third-Party Testing1 flag on record
Visit

Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →

§ 09   Safety

Safety & side effects

Side effects

  • 01Mild grogginess at higher doses

Contraindications

None specified.

§ 10   Questions

DSIP FAQ

What is DSIP?
Nonapeptide associated with delta-wave sleep; used anecdotally for sleep onset and recovery. DSIP's exact mechanism is not fully characterized but appears to modulate corticotropin release, opioid signaling, and slow-wave sleep in some studies. Endogenous distribution across CNS and peripheral tissues.
What is DSIP used for?
Reported uses include potential improvement in deep sleep phases and reduced stress response anecdotally. Evidence strength is rated Experimental — see the evidence section for detail.
How is DSIP dosed?
Commonly referenced dosing is 100 – 500 mcg pre-bed, typically daily, administered SubQ. This is educational reference only; consult a licensed clinician before use.
How do you reconstitute DSIP?
For DSIP, vials commonly come in 5 mg and a common reconstitution is 2 ml BAC water. Use the reconstitution calculator to convert any vial size and water volume into exact insulin-syringe units.
What are the side effects of DSIP?
Commonly reported side effects include mild grogginess at higher doses. This list is not exhaustive.
Is DSIP legal?
Placed on the FDA's 503A Category 2 list and cannot be lawfully compounded in the US. No brand pharmacy alternative exists. US buyers encounter only research-use-only (RUO) channels, which the FDA's Intended Use Doctrine treats as unapproved drug sales. FDA status: Not FDA-approved..

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.